blog
Last updated: 2025-03-14

Cancer Research Update: New Antibody Hv1Lt1 Introduced

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Cancer Research Update: New Antibody Hv1Lt1 Introduced

Cancer Research Update: New Antibody Hv1Lt1 Introduced

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

[New Antibody Hv1Lt1 Opens New Directions for Cancer Treatment]

According to the research report, the antibody Hv1Lt1 can block the activation of the DKK1-CKAP4 pathway in pancreatic cancer and other types of cancer; in mouse experiments, tumor growth was suppressed and the effect of chemotherapy was enhanced. This is still at the research stage.

Key Data:

  • Tumor growth was suppressed in mouse experiments.
  • Enhanced the effects of chemotherapy, further inhibiting cancer cells.
  • Provides a new strategy for cancer treatment.

For more details, please visit: https://tinyurl.com/28lx2sy3

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.

Fukuoka HQ: +81-92-984-3200
Formerly officially certified, No. B-066

Figure 1Figure 1

Figure 2Figure 2

Figure 3Figure 3

Figure 4Figure 4

Related Cancer Information

Related Reading